Expand all sections

Blinatumomab

Blincyto

Extended indication Extension of indication to include treatment as part of consolidation therapy for the treatment of p
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Blinatumomab
Domain Hematology
Reason of inclusion Indication extension
Main indication ALL
Extended indication Extension of indication to include treatment as part of consolidation therapy for the treatment of patients with Philadelphia chromosome negative CD19 positive B-cell precursor ALL
Proprietary name Blincyto
Manufacturer Amgen
Mechanism of action Immunostimulation
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date February 2024
Expected Registration November 2024
Orphan drug Yes
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.